JP2021518162A5 - - Google Patents

Info

Publication number
JP2021518162A5
JP2021518162A5 JP2020573082A JP2020573082A JP2021518162A5 JP 2021518162 A5 JP2021518162 A5 JP 2021518162A5 JP 2020573082 A JP2020573082 A JP 2020573082A JP 2020573082 A JP2020573082 A JP 2020573082A JP 2021518162 A5 JP2021518162 A5 JP 2021518162A5
Authority
JP
Japan
Prior art keywords
item
modified
immunoeffector
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020573082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518162A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022366 external-priority patent/WO2019178422A1/en
Publication of JP2021518162A publication Critical patent/JP2021518162A/ja
Publication of JP2021518162A5 publication Critical patent/JP2021518162A5/ja
Priority to JP2024070727A priority Critical patent/JP2024091902A/ja
Pending legal-status Critical Current

Links

JP2020573082A 2018-03-15 2019-03-14 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 Pending JP2021518162A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024070727A JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US201862643582P 2018-03-15 2018-03-15
US201862643578P 2018-03-15 2018-03-15
US62/643,578 2018-03-15
US62/643,582 2018-03-15
US201862692014P 2018-06-29 2018-06-29
US201862692010P 2018-06-29 2018-06-29
US62/692,010 2018-06-29
US62/692,014 2018-06-29
US201862714337P 2018-08-03 2018-08-03
US201862714333P 2018-08-03 2018-08-03
US62/714,337 2018-08-03
US62/714,333 2018-08-03
US201862768462P 2018-11-16 2018-11-16
US201862768459P 2018-11-16 2018-11-16
US201862768428P 2018-11-16 2018-11-16
US201862768430P 2018-11-16 2018-11-16
US62/768,459 2018-11-16
US62/768,462 2018-11-16
US62/768,430 2018-11-16
US62/768,428 2018-11-16
US201962804259P 2019-02-12 2019-02-12
US62/804,259 2019-02-12
PCT/US2019/022366 WO2019178422A1 (en) 2018-03-15 2019-03-14 Gene-regulating compositions and methods for improved immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024070727A Division JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Publications (2)

Publication Number Publication Date
JP2021518162A JP2021518162A (ja) 2021-08-02
JP2021518162A5 true JP2021518162A5 (enExample) 2022-03-18

Family

ID=67903888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573082A Pending JP2021518162A (ja) 2018-03-15 2019-03-14 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP2024070727A Pending JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024070727A Pending JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Country Status (9)

Country Link
US (2) US20190284529A1 (enExample)
EP (1) EP3765608A4 (enExample)
JP (2) JP2021518162A (enExample)
KR (2) KR20200133218A (enExample)
CN (1) CN112041433A (enExample)
AU (2) AU2019236205A1 (enExample)
BR (1) BR112020018573A2 (enExample)
CA (1) CA3093968A1 (enExample)
WO (1) WO2019178422A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040986A (zh) 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
US20220081691A1 (en) * 2018-08-07 2022-03-17 Dana-Farber Cancer Institute, Inc Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
CN112840026B (zh) * 2018-10-18 2025-01-14 施能康公司 抑制tigit基因表达的组合物和方法
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
US20220096551A1 (en) * 2019-01-28 2022-03-31 Bar Ilan University Combinations, nanoparticles and methods for controlling natural killer cell activation and function
SG11202108452WA (en) * 2019-02-04 2021-09-29 Ksq Therapeutics Inc Combination gene targets for improved immunotherapy
WO2020174472A1 (en) * 2019-02-26 2020-09-03 Rambam Med-Tech Ltd. Cells and methods for improved immunotherapy
US12188045B2 (en) 2019-06-07 2025-01-07 KSQ Therapeutics, Inc. Guide RNA combinations and methods of use
JP2023503652A (ja) * 2019-11-27 2023-01-31 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 腫瘍微小環境における免疫抑制に打ち勝つための操作されたｔ細胞及び腫瘍浸潤リンパ球
CN114929853A (zh) * 2019-11-27 2022-08-19 得克萨斯大学体系董事会 用于治疗胶质母细胞瘤和其他癌症的天然杀伤细胞免疫疗法
AU2020395612A1 (en) * 2019-12-04 2022-06-09 Monash University Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors
WO2021119555A2 (en) * 2019-12-12 2021-06-17 Kumquat Biosciences Inc. Compositions and methods for potentiating immune response
AU2020401376A1 (en) * 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
EP3845646A1 (en) 2019-12-30 2021-07-07 Secarna Pharmaceuticals GmbH & Co. KG Modified antisense oligonucleotide for inhibition of foxp3 expression
CN113151178B (zh) * 2020-01-07 2022-09-09 清华大学 敲除Rc3h1基因和/或Zc3h12a基因的重组T细胞及其应用
TWI895549B (zh) 2020-11-19 2025-09-01 大陸商蘇州沙礫生物科技有限公司 腫瘤浸潤淋巴細胞的培養方法及其用途
WO2022109498A1 (en) * 2020-11-23 2022-05-27 City Of Hope Engineered t cells for expression of chimeric anitgen receptors
EP4255453A4 (en) * 2020-12-03 2025-03-26 Nkarta, Inc. Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
JP7847451B2 (ja) * 2021-03-02 2026-04-17 花王株式会社 アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法
KR20240006612A (ko) * 2021-05-07 2024-01-15 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 (car) t-세포 요법에 관련된 혈청 대사체학
CN113234834A (zh) * 2021-07-09 2021-08-10 北京泱深生物信息技术有限公司 一组用于胰腺癌预后的基因及其应用
US20240360410A1 (en) * 2021-08-03 2024-10-31 Suzhou Grit Biotechnology Co., Ltd. Modified tumor infiltrating lymphocyte and use thereof
WO2023015213A1 (en) * 2021-08-03 2023-02-09 Spotlight Therapeutics Ptpn2 specific guide rnas and uses thereof
CN113430202A (zh) * 2021-08-26 2021-09-24 山东兴瑞生物科技有限公司 一种具有高敲除率的人PD1基因sgRNA及含有该sgRNA的质粒、T细胞
JP2024536839A (ja) * 2021-09-29 2024-10-08 ザ・ジョンズ・ホプキンス・ユニバーシティ 非移植ｃｄ８除去同種ドナーリンパ球輸注の有効性を高め、毒性を低減する方法および組成物
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
GB202114871D0 (en) * 2021-10-18 2021-12-01 Ucl Business Ltd Guide RNA and uses thereof
CN114134177B (zh) * 2021-11-19 2022-11-08 中国医学科学院血液病医院(中国医学科学院血液学研究所) 敲除Setd5的小鼠模型和抵御急性T淋巴细胞白血病小鼠模型的构建方法和应用
CN118401651A (zh) * 2022-01-29 2024-07-26 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
WO2023184107A1 (en) * 2022-03-28 2023-10-05 Huigene Therapeutics Co., Ltd. Crispr-cas13 system for treating mecp2-associated diseases
EP4260932A1 (en) 2022-04-13 2023-10-18 GEA Process Engineering A/S Method and system for reducing water consumption in a membrane dealcoholization process
EP4276174A1 (en) * 2022-05-09 2023-11-15 Cellectis S.A. Gene therapy for the treatment of activated pi3kinase delta syndrome type 1 (apds1)
US20260053921A1 (en) * 2022-08-24 2026-02-26 The Board Of Trustees Of The Leland Stanford Junior University A multiplexed rna regulation platform for primary immune cell engineering
CR20250095A (es) * 2022-09-13 2025-09-01 Arsenal Biosciences Inc Células inmunitarias que coexpresan arnhc de tgfbr
EP4382118B1 (en) * 2022-12-07 2025-08-20 Eberhard Karls Universität Tübingen, Medizinische Fakultät Modified immune cell
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
KR102637929B1 (ko) * 2023-08-07 2024-02-20 충남대학교 산학협력단 면역관문 억제제의 효능 예측용 pbrm1 유전자 마커및 이의 용도
WO2025092690A1 (zh) * 2023-10-30 2025-05-08 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7064193B1 (en) * 1997-09-17 2006-06-20 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
WO2014138348A1 (en) * 2013-03-06 2014-09-12 The Trustees Of The University Of Pennsylvania Iikaros inhibition to augment adoptive t cell transfer
CA2912375C (en) * 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
JP2017524348A (ja) * 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
BR112018003110A2 (pt) * 2015-08-21 2018-09-25 Pfizer nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos

Similar Documents

Publication Publication Date Title
JP2021518161A5 (enExample)
JP2021518160A5 (enExample)
JP7551815B2 (ja) Ｔ細胞療法を向上させるための、哺乳動物ｔ細胞の活性化により誘導可能な合成プロモーター（ｓｙｎ＋ｐｒｏ）の作製
JP2022519595A5 (enExample)
CN110168078B (zh) 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
KR102495308B1 (ko) 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
CN116322716A (zh) Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
KR20210008502A (ko) 암을 치료하기 위한 방법 및 조성물
JP2022519595A (ja) 免疫療法の改善のための遺伝子標的の組み合わせ
US20200017881A1 (en) Programmable Oncolytic Virus Vaccine System and Method
EP3917967A1 (en) Microenvironment sensors to regulate engineered gene expression
JP2025156332A (ja) エクスビボ細胞療法用途のための免疫細胞の操作
JP2022519070A (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
WO2023123195A1 (zh) 一种目的基因可调控的工程化免疫细胞及其制备方法和应用
US20240150711A1 (en) Personalized redirection and reprogramming of t cells for precise targeting of tumors
US20260108604A1 (en) Car t cell compositions for treatment of cancer
Chen et al. Synthetic immunity to break down the bottleneck of cancer immunotherapy
CA3256913A1 (en) NUCLEIC ACID MODIFIED BIOLOGICAL CELL WITH EXPANSION-DEPENDENT GENE EXPRESSION
Navarre et al. Dendritic cells accelerate CAR T cells in irradiated tumors through chimeric synapses
JP2010521460A (ja) 癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制
WO2020190936A1 (en) Chimeric antigen receptors directed to cells expressing the sodium taurocholate co-transporting receptor
Babu et al. Cancer gene therapies progress in pre and postgenomics era
WO2025146440A1 (en) Use of lmo4 to bolster stemness and antitumor efficacy of t-cells
Hagner et al. 646. Covalently-Closed, Dumbbell-Shaped Double-Stem-Loop DNA Constructs (dSLIM) with Specific Immunomodulatory Function
Yoon et al. 116. Overcoming CAR-Dependency of Oncolytic Adenovirus via Adenoviral Fiber Modification with Vesicular Stomatitis Virus Glycoprotein Epitope for Enhanced Antitumor Efficacy